High Growth Tech Stocks In Australia For October 2024

Simply Wall St.
2024-10-15

The Australian market has remained flat over the past week but has experienced a significant 17% increase over the past year, with earnings anticipated to grow by 12% annually in the coming years. In this context, identifying high-growth tech stocks involves looking for companies that not only align with these robust growth expectations but also demonstrate strong innovation and competitive positioning within their sector.

Top 10 High Growth Tech Companies In Australia

Name Revenue Growth Earnings Growth Growth Rating
Clinuvel Pharmaceuticals 22.32% 27.42% ★★★★★★
Adherium 86.80% 73.66% ★★★★★★
ImExHS 20.47% 111.20% ★★★★★★
Telix Pharmaceuticals 20.10% 38.31% ★★★★★★
AVA Risk Group 32.56% 118.83% ★★★★★★
Careteq 37.17% 126.21% ★★★★★☆
Pointerra 56.62% 126.45% ★★★★★★
Wrkr 36.31% 100.29% ★★★★★★
Adveritas 57.98% 144.21% ★★★★★★
SiteMinder 19.65% 60.64% ★★★★★☆

Click here to see the full list of 64 stocks from our ASX High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Nuix

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Nuix Limited is a company that offers investigative analytics and intelligence software solutions across various regions including the Asia Pacific, the Americas, Europe, the Middle East, and Africa, with a market cap of A$2.31 billion.

Operations: Nuix generates revenue primarily from its Software & Programming segment, which accounted for A$220.62 million. The company operates in multiple regions, providing specialized software solutions for investigative analytics and intelligence.

Nuix, recently added to the S&P/ASX 300 and Small Ordinaries Indexes, is navigating a transformative phase with strategic alliances like the one with Veritone, enhancing its eDiscovery and compliance platforms through AI integration. This collaboration aims to streamline complex data analysis, crucial as digital evidence volumes grow. Financially, Nuix turned a profit this year with earnings of AUD 5.03 million from a loss last year and reported an 11.8% revenue increase to AUD 220.62 million. The company's commitment to innovation is evident in its R&D spending which supports its forecasted earnings growth of 40.2% per annum, positioning it favorably in the tech sector despite slower market growth projections.

  • Click here and access our complete health analysis report to understand the dynamics of Nuix.
  • Assess Nuix's past performance with our detailed historical performance reports.

ASX:NXL Earnings and Revenue Growth as at Oct 2024

Pro Medicus

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$19.51 billion.

Operations: The company generates revenue primarily through the production of integrated software applications for the healthcare industry, amounting to A$161.50 million. Its operations span Australia, North America, and Europe.

Pro Medicus demonstrates robust growth with a revenue increase to AUD 166.33 million and net income surging to AUD 82.79 million, reflecting a strong year-over-year performance. The company's strategic emphasis on R&D is evident from its significant investment, aligning with an 18.9% forecasted annual earnings growth, outpacing the Australian market's average of 12.2%. This focus not only fuels innovation but also positions Pro Medicus distinctively in the tech landscape, particularly as it capitalizes on trends like increased demand for advanced medical imaging solutions.

  • Click to explore a detailed breakdown of our findings in Pro Medicus' health report.
  • Examine Pro Medicus' past performance report to understand how it has performed in the past.

ASX:PME Earnings and Revenue Growth as at Oct 2024

REA Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: REA Group Limited operates an online property advertising business across Australia, India, the United States, Malaysia, Singapore, Thailand, Vietnam, and other international markets with a market capitalization of approximately A$28.91 billion.

Operations: The company generates revenue primarily through its property and online advertising segment in Australia, contributing A$1.25 billion, followed by financial services at A$320.6 million and operations in India at A$103.1 million. The focus on digital advertising across diverse markets supports its business model, with a notable emphasis on the Australian market for substantial revenue generation.

REA Group, navigating through a challenging fiscal year with a net income drop to AUD 302.8 million from AUD 356.1 million, still managed to declare an increased dividend of 102 cents per share, up by 23%. This resilience is underscored by its R&D commitment, crucial in the tech-driven real estate sector. Despite a revenue growth forecast at 6.5%, below the high-growth benchmark of 20%, REA's earnings are expected to climb by 16.8% annually, outperforming the Australian market's average of 12.2%. This juxtaposition of declining profits against robust dividends and promising earnings growth highlights REA’s strategic balancing act in enhancing shareholder value while investing in innovation to stay competitive in the evolving digital landscape.

  • Get an in-depth perspective on REA Group's performance by reading our health report here.
  • Learn about REA Group's historical performance.

ASX:REA Earnings and Revenue Growth as at Oct 2024

Turning Ideas Into Actions

  • Access the full spectrum of 64 ASX High Growth Tech and AI Stocks by clicking on this link.
  • Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
  • Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Contemplating Other Strategies?

  • Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
  • Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
  • Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:NXL ASX:PME and ASX:REA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10